BioLife Solutions (BLFS) 10-Q 9 Aug 18 2018 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 07, 2018
Document Information [Line Items]
Entity Registrant Name	BIOLIFE SOLUTIONS INC
Entity Central Index Key	834,365
Trading Symbol	blfs
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		16,461,711
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Amendment Flag	false

Balance Sheets (Current Period

Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 14,166,604	$ 6,663,318
Accounts receivable, trade, net of allowance for doubtful accounts of $0 and $5,575 at June 30, 2018 and December 31, 2017, respectively	2,166,415	1,021,315
Inventories	2,121,881	1,846,746
Prepaid expenses and other current assets	352,507	399,502
Total current assets	18,807,407	9,930,881
Property and equipment
Leasehold improvements	1,284,491	1,284,491
Furniture and computer equipment	693,399	682,466
Manufacturing and other equipment	1,229,318	1,148,006
Subtotal	3,207,208	3,114,963
Less: Accumulated depreciation	(2,163,430)	(2,008,927)
Net property and equipment	1,043,778	1,106,036
Investment in SAVSU	1,899,669	1,070,120
Long term deposits	36,166	36,166
Total assets	21,787,020	12,143,203
Current liabilities
Accounts payable	842,941	690,702
Accrued expenses and other current liabilities	172,879	200,548
Accrued compensation	517,692	491,432
Deferred rent	130,216	130,216
Total current liabilities	1,663,728	1,512,898
Deferred rent, long-term	422,828	492,207
Other long-term liabilities	45,364	45,512
Total liabilities	2,131,920	2,050,617
Commitments and contingencies (Note 9)
Shareholders’ equity
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 3,187 and 4,250 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively	3	4
Common stock, $0.001 par value; 150,000,000 shares authorized, 16,107,505 and 14,021,422 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively	16,107	14,021
Additional paid-in capital	92,653,721	84,036,444
Accumulated deficit	(73,014,731)	(73,957,883)
Total shareholders’ equity	19,655,100	10,092,586
Total liabilities and shareholders’ equity	$ 21,787,020	$ 12,143,203

Balance Sheets (Current Period3

Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Accounts receivable, allowance for doubtful accounts	$ 0	$ 5,575
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	1,000,000	1,000,000
Preferred stock, issued (in shares)	3,187	4,250
Preferred stock, outstanding (in shares)	3,187	4,250
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	16,107,505	14,021,422
Common stock, outstanding (in shares)	16,107,505	14,021,422
Series A Preferred Stock [Member]
Preferred stock, designated (in shares)	4,250	4,250
Preferred stock, outstanding (in shares)	3,187

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Product sales	$ 5,177,854	$ 2,557,765	$ 8,992,736	$ 4,923,966
Cost of product sales	1,536,779	956,839	2,900,608	1,885,241
Gross profit	3,641,075	1,600,926	6,092,128	3,038,725
Operating expenses
Research and development	324,612	318,607	671,066	605,358
Sales and marketing	641,168	546,455	1,252,670	1,058,399
General and administrative	1,390,524	1,077,067	2,743,901	2,180,210
Total operating expenses	2,356,304	1,942,129	4,667,637	3,843,967
Operating income (loss)	1,284,771	(341,203)	1,424,491	(805,242)
Other income (expenses), net
Interest income	32,537	76	40,955	124
Interest expense	(1,332)	(104,582)	(2,232)	(187,915)
Amortization of debt discount		(62,398)		(155,996)
Loss from equity-method investment in SAVSU	(176,798)	(260,105)	(320,554)	(489,473)
Total other income (expenses), net	(145,593)	(427,009)	(281,831)	(833,260)
Net income (loss) before provision for income taxes	1,139,178	(768,212)	1,142,660	(1,638,502)
Income taxes
Net income (loss) after provision for income taxes	1,139,178	(768,212)	1,142,660	(1,638,502)
Less: Preferred stock dividends	(93,258)		(199,508)
Net income (loss) attributable to common stockholders	$ 1,045,920	$ (768,212)	$ 943,152	$ (1,638,502)
Basic net income (loss) per common share (in dollars per share)	$ 0.07	$ (0.06)	$ 0.06	$ (0.13)
Diluted net income (loss) per common share (in dollars per share)	$ 0.05	$ (0.06)	$ 0.05	$ (0.13)
Basic shares used to compute earnings per share (in shares)	15,180,169	13,100,820	14,642,378	13,033,106
Diluted shares used to compute earnings per share (in shares)	20,374,358	13,100,820	19,063,595	13,033,106

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities
Net income (loss)	$ 1,142,660	$ (1,638,502)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Depreciation	161,200	176,251
Stock-based compensation expense	747,805	643,768
Stock issued for services		35,625
Amortization of deferred rent related to lease incentives	(63,499)	(63,499)
Amortization of debt discount		155,996
Loss from equity-method investment in SAVSU	320,554	489,473
Change in operating assets and liabilities
Accounts receivable, trade	(1,145,100)	20,610
Inventories	(275,135)	(11,286)
Prepaid expenses and other current assets	(103,108)	(135,905)
Accounts payable	168,005	(124,239)
Accrued compensation and other current liabilities	5,813	56,442
Accrued interest		185,417
Deferred rent	(5,880)	(62,419)
Net cash provided by (used in) operating activities	953,315	(272,268)
Cash flows from investing activities
Investment in equity investment SAVSU	(1,000,000)
Purchase of property and equipment	(61,479)	(78,185)
Net cash used in investing activities	(1,061,479)	(78,185)
Cash flows from financing activities
Proceeds from related party debt		1,000,000
Payments on equipment loan	(5,441)	(8,176)
Payments on capital lease obligations	(6,541)	(4,360)
Proceeds from exercise of common stock options and warrants	8,898,932	314,024
Payments of preferred stock dividends	(212,500)
Payments for redemption of preferred stock	(1,063,000)
Deferred costs related to potential stock issuance		(42,228)
Net cash provided by financing activities	7,611,450	1,259,260
Net increase in cash and cash equivalents	7,503,286	908,807
Cash and cash equivalents - beginning of period	6,663,318	1,405,826
Cash and cash equivalents - end of period	14,166,604	2,314,633
Non-cash investing and financing activities
Series A preferred stock dividends accrued not yet paid	93,258
Stock issued for services provided in prior period included in liabilities at year-end	35,625	35,624
Receivables converted to equity investment in SAVSU	150,103
Preferred stock issued on conversion of related party note payable and accrued interest		4,250,000
Preferred stock issuance costs not yet paid		8,038
Capital lease obligations incurred for purchases of equipment		52,327
Purchase of equipment with debt	17,604	39,243
Purchase of property and equipment not yet paid	$ 19,859

Note 1 - Organization and Signi

Note 1 - Organization and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. Organization and Significant Accounting Policies Business BioLife Solutions, Inc. (“BioLife,” “us,” “we,” “our,” or the “Company”) is a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media. Our proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. Our biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. Additionally, for our direct, distributor, and contract customers, we perform custom formulation, fill, and finish services. Basis of Presentation We have prepared the accompanying unaudited financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Pursuant to these rules and regulations, we have condensed or omitted certain information and footnote disclosures we normally include in our annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In management’s opinion, we have made all adjustments (consisting only of normal, recurring adjustments) necessary to fairly present our financial position, results of operations and cash flows. Our interim period operating results do not may 10 December 31, 2017 There have been no 10 December 31, 2017, No. 2014 09, 606 Significant Accounting Policies Update Revenue Recognition On January 1, 2018, No. 2014 09, 606 January 1, 2018. January 1, 2018 not 605, not no To determine revenue recognition for contractual arrangements that we determine are within the scope of Topic 606, five five not one We invoice and receive payment from our customers after we recognize revenue, resulting in receivables from our customers that are presented as accounts receivable on our balance sheet. Accounts receivable consist of short-term amounts due from our customers (generally 30 90 Equity Method Investments We account for our ownership in our SAVSU Technologies, Inc. joint venture (“SAVSU”) using the equity method of accounting. This method states that if the investment provides us the ability to exercise significant influence, but not 20% 50%, January 22, 2018, 35%, December 31, 2016, 35% 26.7% three March 31, 2018 30.5% three June 30, 2018 three six June 30, 2018, $0.6 $1.1 $0.2 $0.3 three six June 30, 2017, $0.6 $1.1 45% $0.3 $0.5 Concentrations of credit risk and business risk In the three June 30, 2018, 38% three six June 30, 2018, 27% two three six June 30, 2017, not 10% one No 10% three March 31, 2018 2017. June 30, 2018, three 38% December 31, 2017, two 41% Revenue from customers located in foreign countries represented 11% 13% three six June 30, 2018, 14% 18% three six June 30, 2017, Recent Accounting Pronouncements In August 2016, No. 2016 15, 230 2016 15 January 1, 2018, no In February 2016, No. 2016 02, 842 2016 02 2016 02. December 15, 2018. 2016 02 January 1, 2019. The FASB has issued several additional ASUs that provide additional clarification to certain issues existing after the original ASU was released. In July 2018, 2018 11 842 not July 2018, 2018 10 842 sixteen 2016 02. 2018 11 2018 10 2016 02. 2018 11 2018 10 In January 2016, No. 2016 01, 825 2016 01 January 1, 2018, no With the exception of the new standards discussed above, there have been no not

Note 2 - Fair Value Measurement

Note 2 - Fair Value Measurement	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	2. Fair Value Measurement In accordance with FASB ASC Topic 820, 820” 820 820 three Level 1 Level 2 1 not Level 3 As of June 30, 2018 December 31, 2017, not The following tables set forth the Company’s financial assets measured at fair value on a recurring basis as of June 30, 2018 December 31, 2017, three As of June 30, 2018 Level 1 Level 2 Total Bank deposits $ 14,113,337 $ — $ 14,113,337 Money market funds 53,267 — 53,267 Total cash and cash equivalents $ 14,166,604 $ — $ 14,166,604 As of December 31, 2017 Level 1 Level 2 Total Bank deposits $ 6,610,183 $ — $ 6,610,183 Money market funds 53,135 — 53,135 Total cash and cash equivalents $ 6,663,318 $ — $ 6,663,318 The fair values of bank deposits and money market funds classified as Level 1 no 2 3 not 1 2 six June 30, 2018 twelve December 31, 2017.

Note 3 - Inventory

Note 3 - Inventory	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Inventory Disclosure [Text Block]	3. Inventory Inventory consists of the following at June 30, 2018 December 31, 2017: June 30, 2018 December 31, 2017 Raw materials $ 766,709 $ 582,816 Work in progress 556,054 453,890 Finished goods 799,118 810,040 Total $ 2,121,881 $ 1,846,746

Note 4 - Deferred Rent

Note 4 - Deferred Rent	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Deferred Rent [Text Block]	4. Deferred Rent Deferred rent consists of the following at June 30, 2018 December 31, 2017: June 30, 2018 December 31, 2017 Landlord-funded leasehold improvements $ 1,124,790 $ 1,124,790 Less accumulated amortization (693,024 ) (629,525 ) Total 431,766 495,265 Straight line rent adjustment 121,278 127,158 Total deferred rent $ 553,044 $ 622,423 During the three six June 30, 2018, $31,750 $63,499, three six June 30, 2017, $31,750 $63,499, Straight line rent adjustment represents the difference between cash rent payments and the recognition of rent expense on a straight-line basis over the terms of the lease.

Note 5 - Share-based Compensati

Note 5 - Share-based Compensation	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	5. Share-based Compensation Service Vesting - Based Stock Options The following is a summary of service vesting-based related stock option activity for the six June 30, 2018, June 30, 2018: Six Month Period Ended June 30, 2018 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 2,390,012 $ 1.85 Granted — $ — Exercised (142,914 ) $ 1.19 Forfeited (8,022 ) $ 4.30 Expired — $ — Outstanding service vesting-based at June 30, 2018 2,239,076 $ 1.89 Service vesting-based options exercisable at June 30, 2018 1,652,714 $ 1.80 We recognized stock compensation expense related to service vesting-based options of $149,612 $146,538 three June 30, 2018 2017, $302,315 $316,861 six June 30, 2018 June 30, 2017, June 30, 2018, $21,325,800 $15,888,154 June 30, 2018. three June 30, 2018 2017 $723,532 $21,104, six June 30, 2018 2017 $993,773 $91,817, three June 30, 2018 2017 none six June 30, 2018 2017 none $1.13 June 30, 2018, 5.9 5.5 June 30, 2018 $848,055 1.8 Performance-based Stock Options The Company’s Board of Directors implemented a Management Performance Bonus Plan for 2017. December 31, 2017, 1,000,000 may $1.64, 2017 50% 2017, 50% one not no February 27, 2018, 2017 999,997 50% March 8, 2018 50% March 8, 2019. The following is a summary of performance-based stock option activity for the six June 30, 2018, June 30, 2018: Six Month Period Ended June 30, 2018 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 999,997 $ 1.64 Granted — $ — Exercised (35,000 ) $ 1.64 Outstanding performance-based at June 30, 2018 964,997 $ 1.64 Performance-based options exercisable at June 30, 2018 465,001 $ 1.64 We recognized stock compensation expense related to performance-based options of $126,901 $126,903 three June 30, 2018 2017, $252,408 $252,411 six June 30, 2018 2017. June 30, 2018, $9,428,021 $4,543,060 June 30, 2018. three six June 30, 2018 $285,250 no three six June 30, 2017. June 30, 2018, 3.5 June 30, 2018 $256,592 0.5 The fair value of stock options to employees and non-employee directors is estimated on the measurement date using the Black-Scholes model using the following weighted average assumptions (N/A for 2018 no The fair value of share-based payments made with stock options to employees and non-employee directors was estimated on the measurement date using the Black-Scholes model using the following weighted average assumptions. Three Month Period Ended Six Month Period Ended June 30, June 30, 2018 2017 2018 2017 Risk free interest rate N/A N/A N/A 2.07 % Dividend yield N/A N/A N/A 0.0 % Expected term (in years) N/A N/A N/A 5.18 Volatility N/A N/A N/A 75 % Restricted Stock The following is a summary of restricted stock activity for the six June 30, 2018, June 30, 2018: Six Month Period Ended June 30, 2018 Number of Grant-Date Outstanding at beginning of year 237,926 $ 1.79 Granted 173,768 $ 6.47 Vested (76,538 ) $ 1.79 Forfeited (13,952 ) $ 2.47 Outstanding at June 30, 2018 321,204 $ 4.29 The aggregate fair value of the awards granted during the three six June 30, 2018 $154,440 $1,125,048, three six June 30, 2017 none $364,936, three June 30, 2018 2017 $173,678 $20,123, six June 30, 2018 2017 $480,736 $61,157, We recognized stock compensation expense of $97,867 $40,432 three June 30, 2018 2017, $193,082 $74,496 six June 30, 2018 2017, June 30, 2018, $1,241,718 3.3 We recorded total stock compensation expense for the three six June 30, 2018 2017, Three Month Period Ended Six Month Period Ended June 30, June 30, 2018 2017 2018 2017 Research and development costs $ 64,752 $ 58,815 $ 130,346 $ 118,080 Sales and marketing costs 69,242 58,051 137,755 117,670 General and administrative costs 191,003 154,983 381,953 323,181 Cost of product sales 49,383 42,024 97,751 84,837 Total $ 374,380 $ 313,873 $ 747,805 $ 643,768

Note 6 - Warrants

Note 6 - Warrants	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Warrants [Text Block]	6. Warrants At June 30, 2018 December 31, 2017, 4,863,158 6,688,849 $4.41 $4.50, three six June 30, 2018, 1,813,691 1,825,691 $4.75, $8.6 $8.7 July 30, 2018, 274,798 $4.75, $1.3 March 2021 May 2021.

Note 7 - Income Taxes

Note 7 - Income Taxes	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	7. Income Taxes We have recorded a full valuation allowance against our deferred tax assets. As we trend towards positive net income, we will continue to assess our valuation allowance. Based on all available evidence, we determined that we have not June 30, 2018. may

Note 8 - Earnings Per Share

Note 8 - Earnings Per Share	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	8. Earnings Per Share Basic earnings per share is calculated by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated using the weighted average number of common shares outstanding plus dilutive common stock equivalents outstanding as determined by the treasury method during the period. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect. For the three six June 30, 2018, three six June 30, 2017, 3 7 273,000 The following table shows the calculation of basic and diluted earnings per shares: Three Month Period Ended Six Month Period Ended June 30, June 30, 201 8 201 7 201 8 201 7 Numerator: Net income (loss) attributable to common stockholders $ 1,045,920 $ (768,212 ) $ 943,152 $ (1,638,502 ) Denominator: Weighted average basic shares outstanding 15,180,169 13,100,820 14,642,378 13,033,106 Effect of dilutive securities 5,194,189 — 4,421,217 — Weighted average diluted shares 20,374,358 13,100,820 19,063,595 13,033,106 Basic earnings per share $ 0.07 $ (0.06 ) $ 0.06 $ (0.13 ) Diluted earnings per share $ 0.05 $ (0.06 ) $ 0.05 $ (0.13 )

Note 9 - Commitments & Continge

Note 9 - Commitments & Contingencies	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9 . Commitments & Contingencies Leases We lease approximately 30,000 July 31, 2021 two five first August 1, 2021, second first $58,000 June 30, 2018, August October Employment Agreements We have employment agreements with our Chief Executive Officer, Chief Financial Officer, Chief Technology Officer, Vice President of Operations, Vice President of Marketing, and Vice President of Sales. None may Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none

Note 10 - Preferred Stock

Note 10 - Preferred Stock	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10 . Preferred Stock As of June 30, 2018, $93,258 June 30, 2018. July 2, 2018. May 17, 2018, 1,063 $1,063,000. 3,187 June 30, 2018.

Note 11 - Revenue

Note 11 - Revenue	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	1 1 . Revenue We currently operate as one The following table disaggregates revenue by market segment and distributors: Three Month Period Ended Six Month Period Ended June 30, June 30, 2018 2017 2018 2017 Net product sales: Regenerative medicine $ 2,985,086 $ 1,083,637 $ 5,088,638 $ 2,134,807 Distributors 1,695,153 694,366 2,734,396 1,454,054 Drug discovery 263,023 488,894 639,998 766,808 BioBanking 234,592 290,868 529,704 568,297 Total $ 5,177,854 $ 2,557,765 $ 8,992,736 $ 4,923,966

Note 12 - Subsequent Event

Note 12 - Subsequent Event	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	12. Subsequent Event On August 9, 2018, $20 1,428,571 $14.00 12

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation We have prepared the accompanying unaudited financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Pursuant to these rules and regulations, we have condensed or omitted certain information and footnote disclosures we normally include in our annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In management’s opinion, we have made all adjustments (consisting only of normal, recurring adjustments) necessary to fairly present our financial position, results of operations and cash flows. Our interim period operating results do not may 10 December 31, 2017 There have been no 10 December 31, 2017, No. 2014 09, 606
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition On January 1, 2018, No. 2014 09, 606 January 1, 2018. January 1, 2018 not 605, not no To determine revenue recognition for contractual arrangements that we determine are within the scope of Topic 606, five five not one We invoice and receive payment from our customers after we recognize revenue, resulting in receivables from our customers that are presented as accounts receivable on our balance sheet. Accounts receivable consist of short-term amounts due from our customers (generally 30 90
Equity Method Investments [Policy Text Block]	Equity Method Investments We account for our ownership in our SAVSU Technologies, Inc. joint venture (“SAVSU”) using the equity method of accounting. This method states that if the investment provides us the ability to exercise significant influence, but not 20% 50%, January 22, 2018, 35%, December 31, 2016, 35% 26.7% three March 31, 2018 30.5% three June 30, 2018 three six June 30, 2018, $0.6 $1.1 $0.2 $0.3 three six June 30, 2017, $0.6 $1.1 45% $0.3 $0.5
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of credit risk and business risk In the three June 30, 2018, 38% three six June 30, 2018, 27% two three six June 30, 2017, not 10% one No 10% three March 31, 2018 2017. June 30, 2018, three 38% December 31, 2017, two 41% Revenue from customers located in foreign countries represented 11% 13% three six June 30, 2018, 14% 18% three six June 30, 2017,
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2016, No. 2016 15, 230 2016 15 January 1, 2018, no In February 2016, No. 2016 02, 842 2016 02 2016 02. December 15, 2018. 2016 02 January 1, 2019. The FASB has issued several additional ASUs that provide additional clarification to certain issues existing after the original ASU was released. In July 2018, 2018 11 842 not July 2018, 2018 10 842 sixteen 2016 02. 2018 11 2018 10 2016 02. 2018 11 2018 10 In January 2016, No. 2016 01, 825 2016 01 January 1, 2018, no With the exception of the new standards discussed above, there have been no not

Note 2 - Fair Value Measureme19

Note 2 - Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	As of June 30, 2018 Level 1 Level 2 Total Bank deposits $ 14,113,337 $ — $ 14,113,337 Money market funds 53,267 — 53,267 Total cash and cash equivalents $ 14,166,604 $ — $ 14,166,604 As of December 31, 2017 Level 1 Level 2 Total Bank deposits $ 6,610,183 $ — $ 6,610,183 Money market funds 53,135 — 53,135 Total cash and cash equivalents $ 6,663,318 $ — $ 6,663,318

Note 3 - Inventory (Tables)

Note 3 - Inventory (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2018 December 31, 2017 Raw materials $ 766,709 $ 582,816 Work in progress 556,054 453,890 Finished goods 799,118 810,040 Total $ 2,121,881 $ 1,846,746

Note 4 - Deferred Rent (Tables)

Note 4 - Deferred Rent (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Deferred Rent [Table Text Block]	June 30, 2018 December 31, 2017 Landlord-funded leasehold improvements $ 1,124,790 $ 1,124,790 Less accumulated amortization (693,024 ) (629,525 ) Total 431,766 495,265 Straight line rent adjustment 121,278 127,158 Total deferred rent $ 553,044 $ 622,423

Note 5 - Share-based Compensa22

Note 5 - Share-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Six Month Period Ended June 30, 2018 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 2,390,012 $ 1.85 Granted — $ — Exercised (142,914 ) $ 1.19 Forfeited (8,022 ) $ 4.30 Expired — $ — Outstanding service vesting-based at June 30, 2018 2,239,076 $ 1.89 Service vesting-based options exercisable at June 30, 2018 1,652,714 $ 1.80 Six Month Period Ended June 30, 2018 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 999,997 $ 1.64 Granted — $ — Exercised (35,000 ) $ 1.64 Outstanding performance-based at June 30, 2018 964,997 $ 1.64 Performance-based options exercisable at June 30, 2018 465,001 $ 1.64
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Month Period Ended Six Month Period Ended June 30, June 30, 2018 2017 2018 2017 Risk free interest rate N/A N/A N/A 2.07 % Dividend yield N/A N/A N/A 0.0 % Expected term (in years) N/A N/A N/A 5.18 Volatility N/A N/A N/A 75 %
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Six Month Period Ended June 30, 2018 Number of Grant-Date Outstanding at beginning of year 237,926 $ 1.79 Granted 173,768 $ 6.47 Vested (76,538 ) $ 1.79 Forfeited (13,952 ) $ 2.47 Outstanding at June 30, 2018 321,204 $ 4.29
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Month Period Ended Six Month Period Ended June 30, June 30, 2018 2017 2018 2017 Research and development costs $ 64,752 $ 58,815 $ 130,346 $ 118,080 Sales and marketing costs 69,242 58,051 137,755 117,670 General and administrative costs 191,003 154,983 381,953 323,181 Cost of product sales 49,383 42,024 97,751 84,837 Total $ 374,380 $ 313,873 $ 747,805 $ 643,768

Note 8 - Earnings Per Share (Ta

Note 8 - Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Month Period Ended Six Month Period Ended June 30, June 30, 201 8 201 7 201 8 201 7 Numerator: Net income (loss) attributable to common stockholders $ 1,045,920 $ (768,212 ) $ 943,152 $ (1,638,502 ) Denominator: Weighted average basic shares outstanding 15,180,169 13,100,820 14,642,378 13,033,106 Effect of dilutive securities 5,194,189 — 4,421,217 — Weighted average diluted shares 20,374,358 13,100,820 19,063,595 13,033,106 Basic earnings per share $ 0.07 $ (0.06 ) $ 0.06 $ (0.13 ) Diluted earnings per share $ 0.05 $ (0.06 ) $ 0.05 $ (0.13 )

Note 11 - Revenue (Tables)

Note 11 - Revenue (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Month Period Ended Six Month Period Ended June 30, June 30, 2018 2017 2018 2017 Net product sales: Regenerative medicine $ 2,985,086 $ 1,083,637 $ 5,088,638 $ 2,134,807 Distributors 1,695,153 694,366 2,734,396 1,454,054 Drug discovery 263,023 488,894 639,998 766,808 BioBanking 234,592 290,868 529,704 568,297 Total $ 5,177,854 $ 2,557,765 $ 8,992,736 $ 4,923,966

Note 1 - Organization and Sig25

Note 1 - Organization and Significant Accounting Policies (Details Textual)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2018USD ($)	Mar. 31, 2018	Jun. 30, 2017USD ($)	Mar. 31, 2017	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2017	Jan. 22, 2018
Net Income (Loss) Attributable to Parent, Total	$ 1,139,178		$ (768,212)		$ 1,142,660	$ (1,638,502)
Income (Loss) from Equity Method Investments, Total	$ (176,798)		$ (260,105)		$ (320,554)	$ (489,473)
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Percentage	38.00%	0.00%	0.00%	0.00%	27.00%	0.00%
Number of Major Customers	3				2
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Foreign Countries [Member]
Concentration Risk, Percentage	11.00%		14.00%		13.00%	18.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage					38.00%		41.00%
Number of Major Customers					3		2
SAVSU [Member]
Net Income (Loss) Attributable to Parent, Total	$ (600,000)		$ (600,000)		$ (1,100,000)	$ (1,100,000)
SAVSU [Member]
Equity Method Investment, Ownership Percentage	30.50%	26.70%	45.00%		30.50%	45.00%		35.00%
Income (Loss) from Equity Method Investments, Total	$ (200,000)		$ (300,000)		$ (300,000)	$ (500,000)

Note 2 - Fair Value Measureme26

Note 2 - Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 0	$ 0
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure	$ 0	$ 0

Note 2 - Fair Value Measureme27

Note 2 - Fair Value Measurement - Financial Assets on Recurring Basis (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Fair Value, Inputs, Level 2 [Member]
Total cash and cash equivalents	$ 0	$ 0
Fair Value, Measurements, Recurring [Member]
Total cash and cash equivalents	14,166,604	6,663,318
Fair Value, Measurements, Recurring [Member] | Bank Time Deposits [Member]
Cash and cash equivalents	14,113,337	6,610,183
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]
Cash and cash equivalents	53,267	53,135
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Total cash and cash equivalents	14,166,604	6,663,318
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Bank Time Deposits [Member]
Cash and cash equivalents	14,113,337	6,610,183
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Cash and cash equivalents	53,267	53,135
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Total cash and cash equivalents
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Bank Time Deposits [Member]
Cash and cash equivalents
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Cash and cash equivalents

Note 3 - Inventory - Summary of

Note 3 - Inventory - Summary of Inventory (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Raw materials	$ 766,709	$ 582,816
Work in progress	556,054	453,890
Finished goods	799,118	810,040
Total	$ 2,121,881	$ 1,846,746

Note 4 - Deferred Rent (Details

Note 4 - Deferred Rent (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Amortization of Deferred Rent	$ 31,750	$ 31,750	$ 63,499	$ 63,499

Note 4 - Deferred Rent - Summar

Note 4 - Deferred Rent - Summary of Deferred Rent (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Landlord-funded leasehold improvements	$ 1,124,790	$ 1,124,790
Less accumulated amortization	(693,024)	(629,525)
Total	431,766	495,265
Straight line rent adjustment	121,278	127,158
Total deferred rent	$ 553,044	$ 622,423

Note 5 - Share-based Compensa31

Note 5 - Share-based Compensation (Details Textual) - USD ($)	Feb. 27, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Allocated Share-based Compensation Expense, Total		$ 374,380	$ 313,873	$ 747,805	$ 643,768
Employee Stock Option [Member]
Allocated Share-based Compensation Expense, Total		149,612	146,538	302,315	316,861
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		21,325,800		21,325,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		15,888,154		15,888,154
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 723,532	$ 21,104	$ 993,773	$ 91,817
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0	$ 0	$ 0	$ 1.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term				5 years 328 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term				5 years 182 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 848,055		$ 848,055
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				1 year 292 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				142,914
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				35,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member]
Allocated Share-based Compensation Expense, Total		126,901	$ 126,903	$ 252,408	$ 252,411
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		9,428,021		9,428,021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		4,543,060		4,543,060
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		285,250		285,250
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		256,592		$ 256,592
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				182 days
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price						$ 1.64
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	999,997
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			0		0
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				3 years 182 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				0
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Vesting on Release of Audited Financial Statements for 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						50.00%
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Vesting One Year After Release of Audited Financial Statements for 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						50.00%
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Restricted Stock [Member]
Allocated Share-based Compensation Expense, Total		97,867	$ 40,432	$ 193,082	$ 74,496
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		1,241,718		$ 1,241,718
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				3 years 109 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value		154,440	0	$ 1,125,048	364,936
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 173,678	$ 20,123	$ 480,736	$ 61,157

Note 5 - Share-based Compensa32

Note 5 - Share-based Compensation - Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Employee Stock Option [Member]
Outstanding at beginning of year (in shares) | shares	2,390,012
Outstanding at beginning of year, weighted average exercise price (in dollars per share) | $ / shares	$ 1.85
Granted (in shares) | shares
Granted, weighted average exercise price (in dollars per share) | $ / shares
Exercised (in shares) | shares	(142,914)
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 1.19
Forfeited (in shares) | shares	(8,022)
Forfeited, weighted average exercise price (in dollars per share) | $ / shares	$ 4.30
Expired (in shares) | shares
Expired, weighted average exercise price (in dollars per share) | $ / shares
Outstanding service vesting-based at June 30, 2018 (in shares) | shares	2,239,076
Outstanding service vesting-based at June 30, 2018 (in dollars per share) | $ / shares	$ 1.89
Options exercisable at June 30, 2018 (in shares) | shares	1,652,714
Options exercisable at June 30, 2018 (in dollars per share) | $ / shares	$ 1.80
Performance Shares [Member]
Outstanding at beginning of year (in shares) | shares	999,997
Outstanding at beginning of year, weighted average exercise price (in dollars per share) | $ / shares	$ 1.64
Granted (in shares) | shares
Granted, weighted average exercise price (in dollars per share) | $ / shares
Exercised (in shares) | shares	(35,000)
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 1.64
Outstanding service vesting-based at June 30, 2018 (in shares) | shares	964,997
Outstanding service vesting-based at June 30, 2018 (in dollars per share) | $ / shares	$ 1.64
Options exercisable at June 30, 2018 (in shares) | shares	465,001
Options exercisable at June 30, 2018 (in dollars per share) | $ / shares	$ 1.64

Note 5 - Share-based Compensa33

Note 5 - Share-based Compensation - Fair Value Assumptions (Details) - Employee Stock Option [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Risk free interest rate				2.07%
Dividend yield				0.00%
Expected term (Year)				5 years 65 days
Volatility				75.00%

Note 5 - Share-based Compensa34

Note 5 - Share-based Compensation - Restricted Stock Activity (Details)	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Outstanding at beginning of year (in shares) | shares	237,926
Outstanding at beginning of year (in dollars per share) | $ / shares	$ 1.79
Unvested granted (in shares) | shares	173,768
Granted, grant date fair value (in dollars per share) | $ / shares	$ 6.47
Vested (in shares) | shares	(76,538)
Vested, grant date fair value (in dollars per share) | $ / shares	$ 1.79
Unvested forfeited (in shares) | shares	(13,952)
Forfeited, grant date fair value (in dollars per share) | $ / shares	$ 2.47
Outstanding at June 30, 2018 (in shares) | shares	321,204
Outstanding at June 30, 2018 (in dollars per share) | $ / shares	$ 4.29

Note 5 - Share-based Compensa35

Note 5 - Share-based Compensation - Stock Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Stock compensation expense	$ 374,380	$ 313,873	$ 747,805	$ 643,768
Research and Development Expense [Member]
Stock compensation expense	64,752	58,815	130,346	118,080
Selling and Marketing Expense [Member]
Stock compensation expense	69,242	58,051	137,755	117,670
General and Administrative Expense [Member]
Stock compensation expense	191,003	154,983	381,953	323,181
Cost of Sales [Member]
Stock compensation expense	$ 49,383	$ 42,024	$ 97,751	$ 84,837

Note 6 - Warrants (Details Text

Note 6 - Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended	6 Months Ended
	Aug. 09, 2018	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Class of Warrant or Right, Outstanding		4,863,158	4,863,158	6,688,849
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.41	$ 4.41	$ 4.50
Class of Warrant or Right, Exercised During Period		1,813,691	1,825,691
Class of Warrant or Right, Exercised During Period, Exercise Price		$ 4.75	$ 4.75
Proceeds from Warrant Exercises		$ 8.6	$ 8.7
Subsequent Event [Member]
Class of Warrant or Right, Exercised During Period	274,798
Class of Warrant or Right, Exercised During Period, Exercise Price	$ 4.75
Proceeds from Warrant Exercises	$ 1.3

Note 8 - Earnings Per Share (De

Note 8 - Earnings Per Share (Details Textual) - shares	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,000,000	3,000,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,000,000	7,000,000
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	273,000	273,000

Note 8 - Earnings Per Share - C

Note 8 - Earnings Per Share - Calculation of Diluted Shares (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net income (loss) attributable to common stockholders	$ 1,045,920	$ (768,212)	$ 943,152	$ (1,638,502)
Basic shares used to compute earnings per share (in shares)	15,180,169	13,100,820	14,642,378	13,033,106
Effect of dilutive securities (in shares)	5,194,189		4,421,217
Weighted average diluted shares (in shares)	20,374,358	13,100,820	19,063,595	13,033,106
Basic net income (loss) per common share (in dollars per share)	$ 0.07	$ (0.06)	$ 0.06	$ (0.13)
Diluted net income (loss) per common share (in dollars per share)	$ 0.05	$ (0.06)	$ 0.05	$ (0.13)

Note 9 - Commitments & Contin39

Note 9 - Commitments & Contingencies (Details Textual) - Bothell, Washington Headquarters [Member]	6 Months Ended
	Jun. 30, 2018USD ($)
Lessee, Operating Lease, Renewal Term	5 years
Monthly Base Rent Expense	$ 58,000

Note 10 - Preferred Stock (Deta

Note 10 - Preferred Stock (Details Textual) - USD ($)	May 17, 2018	Jun. 30, 2018	Dec. 31, 2017
Preferred Stock, Shares Outstanding, Ending Balance		3,187	4,250
Series A Preferred Stock [Member]
Stock Redeemed or Called During Period, Shares	1,063
Stock Redeemed or Called During Period, Value	$ 1,063,000
Preferred Stock, Shares Outstanding, Ending Balance		3,187
Accrued Liabilities Current [Member] | Series A Preferred Stock [Member]
Dividends Payable, Current		$ 93,258

Note 11 - Revenue (Details Text

Note 11 - Revenue (Details Textual)	6 Months Ended
	Jun. 30, 2018
Number of Operating Segments	1

Note 11 - Revenue - Disaggregat

Note 11 - Revenue - Disaggregated Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net product sales	$ 5,177,854	$ 2,557,765	$ 8,992,736	$ 4,923,966
Regenerative Medicine [Member]
Net product sales	2,985,086	1,083,637	5,088,638	2,134,807
Distribution Service [Member]
Net product sales	1,695,153	694,366	2,734,396	1,454,054
Drug Discovery [Member]
Net product sales	263,023	488,894	639,998	766,808
BioBanking [Member]
Net product sales	$ 234,592	$ 290,868	$ 529,704	$ 568,297

Note 12 - Subsequent Event (Det

Note 12 - Subsequent Event (Details Textual) - Private Placement [Member] - Casdin Capital LLC [Member] - Subsequent Event [Member] $ / shares in Units, $ in Millions	Aug. 09, 2018USD ($)$ / sharesshares
Proceeds from Issuance of Common Stock | $	$ 20
Stock Issued During Period, Shares, New Issues | shares	1,428,571
Shares Issued, Price Per Share | $ / shares	$ 14